The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease
| Autor: | Christine Collen, Mark De Ridder, Robbe Van den Begin, Benedikt Engels, Tessa de Vin, Emilie Dubaere, Arne Defauw, Kurt Barbé |
|---|---|
| Přispěvatelé: | Faculty of Medicine and Pharmacy, Clinical sciences, Radiation Therapy, Ophtalmology - Eye surgery, Mathematics, Biostatistics and medical informatics, Digital Mathematics, Public Health Sciences, Translational Radiation Oncology and Physics |
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty Lung Neoplasms Population Disease Radiosurgery 030218 nuclear medicine & medical imaging Stereotactic radiotherapy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans risk factors Radiology Nuclear Medicine and imaging Radiosurgery/methods Neoplasm Metastasis Lung cancer education Aged Retrospective Studies education.field_of_study Models Statistical Proportional hazards model business.industry Cancer Hematology Middle Aged Nomogram Lung Neoplasms/mortality Prognosis medicine.disease Colorectal Neoplasms/mortality 030220 oncology & carcinogenesis Female Colorectal Neoplasms aged 80 and over business Brain metastasis |
| Zdroj: | Radiotherapy and Oncology. 133:113-119 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2019.01.001 |
| Popis: | BACKGROUND AND PURPOSE: Stereotactic radiotherapy (SRT, SBRT) is widely used in oligometastatic cancer, but the heterogeneity of the population complicates estimation of the prognosis. We investigated the role of different clinical and inflammatory parameters. MATERIALS AND METHODS: We included all patients treated with SRT for 1-5 oligometastases between 2003 and 2017 in our center. Patients were randomized between a model training set (2/3) and a separate validation set (1/3). A Cox regression model was built, validated and risk points were attributed to the resulting parameters. RESULTS: 403 patients received SRT for 760 metastases. Treated sites were mainly lung, liver, nodal areas, and brain. Most common primaries were colorectal and lung cancer. Median follow-up for living patients reached 42 months and median overall survival (MS) was 26.6 months (95% CI 23.8-29.3). Five independent adverse factors were discriminated: male sex, synchronous timing of oligometastases, brain metastasis, non-adenocarcinoma histology, KPS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect